<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39415081</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>17</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1471-2334</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>16</Day></PubDate></JournalIssue><Title>BMC infectious diseases</Title><ISOAbbreviation>BMC Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Impact of FCGR2A rs1801274 and IL-6R rs2228145 polymorphisms on tocilizumab response in the Iranian population with severe COVID-19.</ArticleTitle><Pagination><StartPage>1168</StartPage><MedlinePgn>1168</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1168</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12879-024-10073-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although several genetic biomarkers have been reported in the tocilizumab (TCZ) response in rheumatoid arthritis, no studies have addressed the pharmacogenomics effect of TCZ in COVID-19.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this prospective longitudinal study, 95 individuals with severe COVID-19 were selected between 2020-2022. The recovery process was measured at 24 h, 48 h, and 10 days before and after taking TCZ. All participants were genotyped using RFLP-PCR. Different genotypes of FCGR2A rs1801274 and IL-6R rs2228145 were compared in terms of the recovery process.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">43.2% of patients were male and 56.8% were female with an average age of 58.20(± 16.214) years. The GA genotype for FCGR2A rs1801274 increased the risk of death (OR = 2.83, P = 0.038) and ventilation (OR = 2.71, P = 0.047) in TCZ-treated individuals. However, there was no risk of death and ventilation with IL-6R rs2228145 (P &gt; 0.05). Additionally, docking analysis showed that not only IL6R but also FCGR2A can be a ligand for TCZ.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study provides valuable insights into the impact of genetic variations on the response rate of TCZ in COVID-19 patients. The GA genotype for FCGR2A rs1801274 was associated with poor treatment outcomes.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Injinari</LastName><ForeName>Nastaran</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5524-5388</Identifier><AffiliationInfo><Affiliation>Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asadollahi</LastName><ForeName>Samira</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-6712-0504</Identifier><AffiliationInfo><Affiliation>Research Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sefid</LastName><ForeName>Fateme</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-0867-9305</Identifier><AffiliationInfo><Affiliation>Department of Genetics, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arshadi</LastName><ForeName>Maedeh</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7696-5042</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hosseini</LastName><ForeName>Saeedeh Sadat</ForeName><Initials>SS</Initials><Identifier Source="ORCID">0000-0002-9613-1296</Identifier><AffiliationInfo><Affiliation>Research Center for Food Hygiene and Safety, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ghoshouni</LastName><ForeName>Hamed</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0001-8949-2256</Identifier><AffiliationInfo><Affiliation>Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rajaie Cardiovascular Medical and Research Center, Iran University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Soltani</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0006-3694-657X</Identifier><AffiliationInfo><Affiliation>Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Namiranian</LastName><ForeName>Nasim</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-5133-6204</Identifier><AffiliationInfo><Affiliation>Diabetes Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikhha</LastName><ForeName>Mohammad Hasan</ForeName><Initials>MH</Initials><Identifier Source="ORCID">0000-0002-3734-8970</Identifier><AffiliationInfo><Affiliation>Abortion Research Centre, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Science, Yazd, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aghaeimeybodi</LastName><ForeName>Fatemeh</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5132-2494</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Shahid Sadoughi University of Medical Sciences, Daneshjoo Blvd, Yazd, Iran. drmeybodi@gmail.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Infect Dis</MedlineTA><NlmUniqueID>100968551</NlmUniqueID><ISSNLinking>1471-2334</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C445323">FCGR2A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D017452">Receptors, IgG</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508603">IL6R protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017452" MajorTopicYN="Y">Receptors, IgG</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="Y">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019947" MajorTopicYN="Y">Receptors, Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="Y">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007492" MajorTopicYN="N" Type="Geographic">Iran</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">FCGR2A</Keyword><Keyword MajorTopicYN="N">IL-6 receptor</Keyword><Keyword MajorTopicYN="N">Polymorphism</Keyword><Keyword MajorTopicYN="N">Tocilizumab</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>17</Day><Hour>10</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>23</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39415081</ArticleId><ArticleId IdType="pmc">PMC11481263</ArticleId><ArticleId IdType="doi">10.1186/s12879-024-10073-0</ArticleId><ArticleId IdType="pii">10.1186/s12879-024-10073-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO). Weekly Epidemiological Update–12 October 2020. Diunduh dari; 2020. https://www.who.int/publications/m/item/weekly-epidemiological-update---12-october-2020.</Citation></Reference><Reference><Citation>Mehrizi R, Golestani A, Malekpour MR, Karami H, Nasehi MM, Effatpanah M, et al. Patterns of case fatality and hospitalization duration among nearly 1 million hospitalized COVID-19 patients covered by Iran Health Insurance Organization (IHIO) over two years of pandemic: An analysis of associated factors. PLoS One. 2024;19(2):e0298604. Available from: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0298604. Cited 2024 Jun 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10889889</ArticleId><ArticleId IdType="pubmed">38394118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmanzade R, Rahmanzadeh R, Hashemian SMR, Tabarsi P. Iran’s Approach to COVID-19: Evolving Treatment Protocols and Ongoing Clinical Trials. Front Public Heal. 2020;8. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7498537/. Cited 2024 Jun 9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7498537</ArticleId><ArticleId IdType="pubmed">33014984</ArticleId></ArticleIdList></Reference><Reference><Citation>Maldonado-Montoro M, Cañadas-Garre M, González-Utrilla A, Plaza-Plaza JC, Calleja-Hernández MÁ. Genetic and clinical biomarkers of tocilizumab response in patients with rheumatoid arthritis. Pharmacol Res. 2016;1(111):264–71.</Citation><ArticleIdList><ArticleId IdType="pubmed">27339827</ArticleId></ArticleIdList></Reference><Reference><Citation>Pelaia C, Calabrese C, Garofalo E, Bruni A, Vatrella A, Pelaia G, et al. Molecular Sciences Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence. 2021; Available from: 10.3390/ijms22063059. Cited 2023 Aug 11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8002419</ArticleId><ArticleId IdType="pubmed">33802761</ArticleId></ArticleIdList></Reference><Reference><Citation>Khiali S, Khani E, Entezari‐Maleki T. A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome. J Clin Pharmacol. 2020;60(9):1131–46. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jcph.1693. Cited 2020 Dec 14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jcph.1693</ArticleId><ArticleId IdType="pmc">PMC7323169</ArticleId><ArticleId IdType="pubmed">32557541</ArticleId></ArticleIdList></Reference><Reference><Citation>Tleyjeh IM, Kashour Z, Damlaj M, Riaz M, Tlayjeh H, Altannir M, et al. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis. Clin Microbiol Infect. 2021;27(2):215–27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7644182</ArticleId><ArticleId IdType="pubmed">33161150</ArticleId></ArticleIdList></Reference><Reference><Citation>Biran N, Ip A, Ahn J, Go RC, Wang S, Mathura S, et al. Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. Lancet Rheumatol. 2020;2(10):e603–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7428303</ArticleId><ArticleId IdType="pubmed">32838323</ArticleId></ArticleIdList></Reference><Reference><Citation>Lan SH, Lai CC, Huang HT, Chang SP, Lu LC, Hsueh PR. Tocilizumab for severe COVID-19: a systematic review and meta-analysis. Int J Antimicrob Agents. 2020;56(3):106103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377685</ArticleId><ArticleId IdType="pubmed">32712333</ArticleId></ArticleIdList></Reference><Reference><Citation>Huddart R, Whirl‐Carrillo M, Altman RB, Klein TE. PharmGKB Tutorial for Pharmacogenomics of Drugs Potentially Used in the Context of COVID‐19. Clin Pharmacol Ther. 2021;109(1):116–22. Available from: https://onlinelibrary.wiley.com/doi/10.1002/cpt.2067. Cited 2020 Dec 30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2067</ArticleId><ArticleId IdType="pmc">PMC7537078</ArticleId><ArticleId IdType="pubmed">32978778</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T, Luzum JA, Nicol MR, Jacobson PA. Pharmacogenomics of COVID-19 therapies. Available from: 10.1038/s41525-020-00143-y. Cited 2020 Dec 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435176</ArticleId><ArticleId IdType="pubmed">32864162</ArticleId></ArticleIdList></Reference><Reference><Citation>Cafiero C, Re A, Micera A, Palmirotta R, Monaco D, Romano F, et al. Pharmacogenomics and pharmacogenetics: In silico prediction of drug effects in treatments for novel coronavirus SARS-CoV2 disease. Pharmgenomics Pers Med. 2020;13:463–84. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568633/?report=abstract. Cited 2020 Dec 30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7568633</ArticleId><ArticleId IdType="pubmed">33116761</ArticleId></ArticleIdList></Reference><Reference><Citation>Smieszek SP, Przychodzen BP, Polymeropoulos VM, Polymeropoulos CM, Polymeropoulos MH. Assessing the potential correlation of polymorphisms in the IL6R with relative IL6 elevation in severely ill COVID-19 patients’. Cytokine. 2021;148. Available from: 
https://pubmed.ncbi.nlm.nih.gov/34353696/. Cited 2024 Jun 22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8318728</ArticleId><ArticleId IdType="pubmed">34353696</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotch C, Barrett D, Teachey DT. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Vol. 15, Expert Review of Clinical Immunology. Taylor and Francis Ltd; 2019. p. 813–22. Available from: https://www.tandfonline.com/doi/abs/10.1080/1744666X.2019.1629904. Cited 2020 Dec 17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1744666X.2019.1629904</ArticleId><ArticleId IdType="pmc">PMC7936577</ArticleId><ArticleId IdType="pubmed">31219357</ArticleId></ArticleIdList></Reference><Reference><Citation>Roederer M, Quaye L, Mangino M, Beddall MH, Mahnke Y, Chattopadhyay P, et al. The Genetic Architecture of the Human Immune System: A Bioresource for Autoimmunity and Disease Pathogenesis. Cell. 2015;161(2):387–403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4393780</ArticleId><ArticleId IdType="pubmed">25772697</ArticleId></ArticleIdList></Reference><Reference><Citation>Roca L, Diéras V, Roché H, Lappartient E, Kerbrat P, Cany L, et al. Correlation of HER2, FCGR2A, and FCGR3A gene polymorphisms with trastuzumab related cardiac toxicity and efficacy in a subgroup of patients from UNICANCER-PACS04 trial. Breast Cancer Res Treat. 2013;139(3):789–800. Available from: hhttps://link.springer.com/article/10.1007/s10549-013-2587-x. Cited 2022 Oct 26.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10549-013-2587-x</ArticleId><ArticleId IdType="pubmed">23780683</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahlqvist J, Fulco CP, Ray JP, Liechti T, De Boer CG, Lieb DJ, et al. Systematic identification of genomic elements that regulate FCGR2A expression and harbor variants linked with autoimmune disease. Hum Mol Genet. 2022;31(12):1946–61. Available from: 
https://academic.oup.com/hmg/article/31/12/1946/6490623. Cited 2022 Oct 26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9239749</ArticleId><ArticleId IdType="pubmed">34970970</ArticleId></ArticleIdList></Reference><Reference><Citation>Klopfenstein T, Gendrin V, Kadiane-Oussou NJ, Conrozier T, Zayet S. Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials. Rev Med Virol. 2022;32(1):e2239. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/rmv.2239. Cited 2022 Oct 22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2239</ArticleId><ArticleId IdType="pmc">PMC8250236</ArticleId><ArticleId IdType="pubmed">33882179</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikulska M, Nicolini LA, Signori A, Di Biagio A, Sepulcri C, Russo C, et al. Tocilizumab and steroid treatment in patients with COVID-19 pneumonia. Adrish M, editor. PLoS One. 2020;15(8):e0237831. Available from: https://dx.plos.org/10.1371/journal.pone.0237831. Cited 2020 Dec 14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0237831</ArticleId><ArticleId IdType="pmc">PMC7440633</ArticleId><ArticleId IdType="pubmed">32817707</ArticleId></ArticleIdList></Reference><Reference><Citation>Malekzadeh R, Abedini A, Mohsenpour B, Sharifipour E, Ghasemian R, Javad-Mousavi SA, et al. Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial. Int Immunopharmacol. 2020;89:107102. Available from: 10.1016/j.intimp.2020.107102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7553010</ArticleId><ArticleId IdType="pubmed">33075713</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomasiewicz K, Piekarska A, Stempkowska-Rejek J, Serafińska S, Gawkowska A, Parczewski M, et al. Tocilizumab for patients with severe COVID-19: a retrospective, multi-center study. Expert Rev Anti Infect Ther. 2020;1–8. Available from: https://www.tandfonline.com/doi/full/10.1080/14787210.2020.1800453. Cited 2020 Dec 14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14787210.2020.1800453</ArticleId><ArticleId IdType="pmc">PMC7441800</ArticleId><ArticleId IdType="pubmed">32693650</ArticleId></ArticleIdList></Reference><Reference><Citation>Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021;27(1):52–66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7369580</ArticleId><ArticleId IdType="pubmed">32713784</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Duan X, Wang T, Feng X, Wang P, Yao W, et al. Detection of the rs10250202 polymorphism in protection of telomeres 1 gene through introducing a new restriction enzyme site for PCR–RFLP assay. Springerplus. 2016;5(1):1–6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4864762</ArticleId><ArticleId IdType="pubmed">27247888</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X, Brennan BJ. Disease–Drug–Drug Interaction Assessments for Tocilizumab—A Monoclonal Antibody against Interleukin-6 Receptor to Treat Patients with Rheumatoid Arthritis. Pharm Sci Encycl. 2013;1–16. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/9780470571224.pse482. Cited 2023 Aug 8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/9780470571224.pse482</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomaszewska-Kiecana M, Ullmann M, Petit-Frere C, Monnet J, Dagres C, Illes A. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults. Expert Rev Clin Immunol. 2023;19(4):439–46. Available from: 10.1080/1744666X.2023.2174104. Cited 2023 Aug 8.</Citation><ArticleIdList><ArticleId IdType="pubmed">36715299</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagelkerke SQ, Schmidt DE, de Haas M, Kuijpers TW. Genetic Variation in Low-To-Medium-Affinity Fcγ Receptors: Functional Consequences, Disease Associations, and Opportunities for Personalized Medicine. Front Immunol. 2019;10(October):1–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6786274</ArticleId><ArticleId IdType="pubmed">31632391</ArticleId></ArticleIdList></Reference><Reference><Citation>Osborne JM, Chacko GW, Brandt JT, Anderson CL. Ethnic variation in frequency of an allelic polymorphism of human Fcγ RIIA determined with allele specific oligonucleotide probes. J Immunol Methods. 1994;173(2):207–17.</Citation><ArticleIdList><ArticleId IdType="pubmed">8046255</ArticleId></ArticleIdList></Reference><Reference><Citation>Stein MM, Hrusch CL, Sperling AI, Ober C. Effects of an FcγRIIA polymorphism on leukocyte gene expression and cytokine responses to anti-CD3 and anti-CD28 antibodies. Genes Immun. 2019;20(6):462–72. Available from: 10.1038/s41435-018-0038-8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8026236</ArticleId><ArticleId IdType="pubmed">29977032</ArticleId></ArticleIdList></Reference><Reference><Citation>Enevold C, Baslund B, Linde L, Josephsen NL, Tarp U, Lindegaard H, et al. Interleukin-6-receptor polymorphisms rs12083537, rs2228145, and rs4329505 as predictors of response to tocilizumab in rheumatoid arthritis. Pharmacogenet Genomics. 2014;24(8):401–5.</Citation><ArticleIdList><ArticleId IdType="pubmed">24978393</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Bansal AT, Martin M, Germer S, Benayed R, Essioux L, et al. Genome-wide association analysis implicates the involvement of eight loci with response to tocilizumab for the treatment of rheumatoid arthritis. Pharmacogenomics J. 2013;13(3):235–41. Available from: 
https://www.nature.com/tpj. Cited 2020 Dec 30.</Citation><ArticleIdList><ArticleId IdType="pubmed">22491018</ArticleId></ArticleIdList></Reference><Reference><Citation>Luxembourger C, Ruyssen-Witrand A, Ladhari C, Rittore C, Degboe Y, Maillefert JF, et al. A single nucleotide polymorphism of IL6-receptor is associated with response to tocilizumab in rheumatoid arthritis patients. Pharmacogenomics J. 2019;19(4):368–74. Available from: 
http://www.nature.com/articles/s41397-019-0072-6. Cited 2020 Dec 17.</Citation><ArticleIdList><ArticleId IdType="pubmed">30647443</ArticleId></ArticleIdList></Reference><Reference><Citation>González-Medina M, Dávila-Fajardo C, Soto-Pino M, Díaz-Villamarín X, Gómez-Martín A, Martínez-González L, et al. PKP-024 The FCGR2A (A &gt;G) (RS1801274) genetic variant and the efficacy of tocilizumab in rheumatoid arthritis patients. Eur J Hosp Pharm. 2016 ;23(Suppl 1):A189–A189. Available from: 
https://ejhp.bmj.com/content/23/Suppl_1/A189.1. Cited 2023 Aug 8.</Citation></Reference><Reference><Citation>Rafiq S, Frayling TM, Murray A, Hurst A, Stevens K, Weedon MN, et al. A common variant of the interleukin 6 receptor (IL-6r) gene increases IL-6r and IL-6 levels, without other inflammatory effects. Genes Immun 2007 87. 2007;8(7):552–9. Available from: 
https://www.nature.com/articles/6364414. Cited 2023 Aug 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2668154</ArticleId><ArticleId IdType="pubmed">17671508</ArticleId></ArticleIdList></Reference><Reference><Citation>Sainz L, Riera P, Moya P, Bernal S, Casademont J, Díaz-Torné C, et al. Role of IL6R Genetic Variants in Predicting Response to Tocilizumab in Patients with Rheumatoid Arthritis. Pharm. 2022;14:1942. Available from: 
https://www.mdpi.com/1999-4923/14/9/1942/htm. Cited 2023 Aug 13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9501307</ArticleId><ArticleId IdType="pubmed">36145690</ArticleId></ArticleIdList></Reference><Reference><Citation>Karcioglu Batur L, Hekim N. Correlation between interleukin gene polymorphisms and current prevalence and mortality rates due to novel coronavirus disease 2019 (COVID-2019) in 23 countries. J Med Virol. 2021;93(10):5853–63. Available from: https://onlinelibrary.wiley.com/doi/full/10.1002/jmv.27127. Cited 2023 Aug 9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27127</ArticleId><ArticleId IdType="pmc">PMC8242628</ArticleId><ArticleId IdType="pubmed">34081354</ArticleId></ArticleIdList></Reference><Reference><Citation>Lundstrom K, Hromić-Jahjefendić A, Bilajac E, Aljabali AAA, Baralić K, Sabri NA, et al. COVID-19 signalome: Pathways for SARS-CoV-2 infection and impact on COVID-19 associated comorbidity. Cell Signal. 2023;1(101):110495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9568271</ArticleId><ArticleId IdType="pubmed">36252792</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Song F, Guo W, Tan J, Zhang X, Qiao F, et al. Potential Genes Associated with COVID-19 and Comorbidity. Int J Med Sci. 2022;19(2):402. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795808/. Cited 2023 Aug 15.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8795808</ArticleId><ArticleId IdType="pubmed">35165525</ArticleId></ArticleIdList></Reference><Reference><Citation>Crimi E, Benincasa G, Figueroa-Marrero N, Galdiero M, Napoli C. Epigenetic susceptibility to severe respiratory viral infections and its therapeutic implications: a narrative review. Br J Anaesth. 2020;125(6):1002–17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438995</ArticleId><ArticleId IdType="pubmed">32828489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayipo YO, Ajiboye AT, Osunniran WA, Jimoh AA, Mordi MN. Epigenetic oncogenesis, biomarkers and emerging chemotherapeutics for breast cancer. Biochim Biophys Acta - Gene Regul Mech. 2022;1865(7):194873.</Citation><ArticleIdList><ArticleId IdType="pubmed">36064110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>